News | October 24, 2013

Transcatheter Technologies Successfully Implants Human With Repositionable Trinity Transapical Aortic Valve

Clinical data to be presented at TCT 2013

heart valve repair clinical trial study transcatheter aortic valve trinity
October 24, 2013 — Transcatheter Technologies GmbH, a medical device company, announced the successful first-in-human implantation of its transapical Trinity aortic valve.
 
“A major limitation of existing transcatheter aortic heart valves is that they cannot be repositioned once implanted. Trinity, however, is designed to solve this difficult problem,” said Wolfgang Goetz, M.D., Ph.D., CEO, Transcatheter Technologies. “With Trinity, once our valve is initially placed, a cardiologist can fully evaluate the valve’s function to determine whether it needs to be repositioned, retrieved or kept in the same position.  Equally important, Trinity provides for a controlled positioning by allowing a cardiologist to slowly open the valve stent, thus improving the likelihood of a first-attempt correct placement.”
 
“The Trinity aortic valve can be positioned precisely. Yet, it also allows for safe repositioning of the valve prosthesis — or even full retrieval — if necessary. Its unique sealing cuff provides excellent results without paravalvular leakage. Moreover, the risk for atrio-ventricular block is dramatically reduced due to the supraannular positioning of Trinity,” said Dr. Christian Hengstenberg, cardiologist, German Heart Centre, Munich, Germany.
 
The results of the first-in-human clinical trial using Trinity will be presented at the annual Transcatheter Cardiovascular Therapeutics (TCT) Meeting on Oct. 28, 2013 in San Francisco.
 
For more information: www.transcathetertechnologies.com
 

Related Content

Lexington Begins HeartSentry Clinical Trial
News | Clinical Study | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Clinical Study | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Clinical Study | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Clinical Study | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Clinical Study | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Clinical Study | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init